$TRAX News

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

Assessing AnaptysBio (ANAB) Valuation After Royalty Pivot Spinoff And Legal Outcome

Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

First Tracks Biotherapeutics Files Resale Prospectus For 10,497,054 Common Shares

First Tracks: Huge Cash Reserves Will Not Sustain Testing For Long

Piper Sandler Initiates Coverage On First Tracks with Overweight Rating, Announces Price Target of $54

First Tracks Biotherapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a $30 price target.

First Tracks Biotherapeutics shares are trading higher after HC Wainwright & Co. initiated coverage on the stock with a Buy rating and announced a $30 price target.

HC Wainwright & Co. Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $30

First Tracks shares are trading higher after Leerink Partners initiated coverage on the stock with Outperform rating and announced a $46 price target.

Leerink Partners Initiates Coverage On First Tracks with Outperform Rating, Announces Price Target of $46

JP Morgan Initiates Coverage On First Tracks with Overweight Rating, Announces Price Target of $31

Barclays Initiates Coverage On First Tracks with Overweight Rating, Announces Price Target of $40

UBS Initiates Coverage On First Tracks with Buy Rating, Announces Price Target of $45

First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases